Cookies on this website
We use cookies to ensure that we give you the best experience on our website. If you click 'Continue' we'll assume that you are happy to receive all cookies and you won't see this message again. Click 'Find out more' for information on how to change your cookie settings.

OBJECTIVE: To examine fine specificity of anticitrullinated peptide antibodies (ACPA) in relation to responsiveness to anti-tumor necrosis factor (anti-TNF) agents in rheumatoid arthritis (RA). METHODS: Samples from 450 patients with RA treated with anti-TNF agents were analyzed for antibodies to citrullinated α-enolase, vimentin, and fibrinogen peptides. The Disease Activity Score-28 was measured at baseline and 6 months. RESULTS: Both anti-cFib antibodies and the number of citrullinated peptides recognized were associated with a poorer response. These findings were not significant following stratification for anti-cyclic citrullinated peptide 2 antibodies. CONCLUSION: The presence of any ACPA rather than individual ACPA specificities was associated with a poorer response to anti-TNF agents. We suggest that this reflects distinctive differences in the pathogenesis of ACPA-positive and negative RA.

Original publication

DOI

10.3899/jrheum.111315

Type

Journal article

Journal

J Rheumatol

Publication Date

05/2012

Volume

39

Pages

929 - 932

Keywords

Aged, Antibody Specificity, Antirheumatic Agents, Arthritis, Rheumatoid, Autoantibodies, Biomarkers, Tumor, DNA-Binding Proteins, Female, Fibrinogen, Humans, Male, Middle Aged, Peptides, Cyclic, Phosphopyruvate Hydratase, Tumor Necrosis Factor-alpha, Tumor Suppressor Proteins, Vimentin